# Reflection

## Biggest Unresolved Risks

### 1. Recommendation Quality And Clinician Trust

This remains the biggest product risk. If the recommendation is incomplete, stale, or not actionable, clinicians will treat it like another low-value alert. The product only works if clinicians believe it helps them make a better prescribing decision in the room.

### 2. Data Quality And Freshness

Even strong models will fail if payer rules, routing logic, formulary status, or affordability signals are missing or stale. In this category, being directionally wrong can destroy trust quickly because the user is making a real patient-facing decision.

### 3. Workflow Adoption

The concept is strong only if it appears at the right moment with very low friction. A useful recommendation that arrives too late or requires too many clicks will still lose to clinician inertia.

### 4. Regulatory And Positioning Risk

The product must remain clearly positioned as an access-feasibility assistant, not an autonomous therapy-selection engine. If it is framed as choosing the best treatment rather than supporting executable prescribing, regulatory scrutiny and organizational resistance both increase.

## Tradeoffs In The Chosen MVP

The `90-day MVP` deliberately chooses:

- `Explainability over automation`
- `Workflow adjacency over deep integration`
- `Narrow specialty scope over broad coverage`
- `Clinician control over autonomous action`

These are the right tradeoffs for launch because they reduce build risk, implementation risk, and trust risk. But they also create limitations. Without deep `EHR` integration, some context will be missing. Without downstream automation, ROI may take longer to prove. Without coordinator workflow support, not all operational pain is solved in version one.

I would still defend these choices because the first question to answer is simpler: can we influence prescribing decisions early enough to reduce avoidable access failure? If that answer is no, deeper integration and automation will not rescue the product.

## What I Learned From This Scope Choice

The most important insight is that the wedge should not be `prior auth prediction`. That is too narrow and too easy to compare against existing infrastructure vendors. The stronger wedge is `executable prescribing`: helping clinicians understand whether the chosen therapy is realistically startable and what to do if it is not.

I also think the communication-support component is more strategically important than it first appears. Medication access problems do not only create operational friction. They also create patient confusion and mistrust. Helping the clinician explain likely barriers and next steps may be a key adoption driver, especially before the recommendation engine is perfect.

## If Early Results Are Mixed

I would not immediately scale and I would not immediately kill the concept. I would narrow further.

Most likely next moves:

- Focus on a single specialty and a smaller set of high-friction therapies.
- Improve curated access logic before expanding model ambition.
- Add stronger human feedback loops from coordinators and pharmacists.
- Introduce limited read-only `EHR` context only where it materially improves accuracy.
- Reposition the product around `access transparency + patient expectation setting` if communication support proves stronger than recommendation trust.

## What I Would Do Next

If the early signals are promising, the next phase should be selective, not broad. I would add read-only `EHR` context, improve input completeness, and deepen workflow fit in the best-performing specialty before expanding across specialties. I would also begin proving the buyer ROI story with harder metrics such as time to therapy, first-fill success, and rework reduction.

If the early signals are weak, I would ask whether the problem is the model, the workflow entry point, or the wedge itself. That distinction matters. A recommendation engine that clinicians trust but rarely open needs better workflow insertion. A tool that clinicians open but do not trust needs narrower scope and better data. A tool that does neither likely needs product repositioning before more investment.

## case study-Ready Framing

My reflection is that the MVP is intentionally conservative in the right ways. It avoids deep integration, automation, and broad scope so the team can answer the most important question first: can we deliver trusted, explainable access guidance early enough in the prescribing moment to change what happens next? If yes, there is a credible expansion path. If no, the right response is to narrow or reposition before scaling complexity.
